Showing 2671-2680 of 3223 results for "".
- Glaukos Submits Supplemental Pre-Market Approval Application for iStent Infinitehttps://modernod.com/news/glaukos-submits-supplemental-pre-market-approval-application-for-istent-infinite/2479482/Glaukos announced that it has submitted a supplemental pre-market approval (PMA) application to the FDA for the iStent infinite Trabecular Micro-Bypass System. The iStent infinite is an investigational device designed for use in a standalone procedure to reduce elevated IOP in p
- New Virtual Training Takes on Leading Cause of Childhood Blindnesshttps://modernod.com/news/new-virtual-training-takes-on-leading-cause-of-childhood-blindness/2479471/Orbis International, with support from Alcon, launched a new virtual Flying Eye Hospital project that will train eye care professionals across Latin America to treat retinopathy of prematurity (ROP), the leading cause of blindness among children worldwide. Affecti
- Glaucoma Devices’ Expanding Role to Drive Double-Digit Market Growthhttps://modernod.com/news/glaucoma-devices-expanding-role-to-drive-double-digit-market-growth/2479465/Glaucoma surgical devices will see increased use in all stages of disease and in stand-alone glaucoma procedures over the next 5 years, as companies commercialize more devices designed to meet these needs, according to a Market Scope report. Market Scope expects the glaucoma surgical devi
- Glaucoma Research Foundation Receives $1.5 Million Gift For Collaborative Vision Restoration Initiativehttps://modernod.com/news/glaucoma-research-foundation-receives-1-5-million-gift-for-collaborative-vision-restoration-initiative/2479460/Glaucoma Research Foundation announced the receipt of a $1.5 million matching gift from Steve and Michele Kirsch of Palo Alto, California. The gift will help fund the Foundation’s collaborat
- Visus Therapeutics Expands Ophthalmic Drug Portfolio With Investigational Therapies for Glaucoma and AMDhttps://modernod.com/news/visus-therapeutics-expands-ophthalmic-drug-portfolio-with-investigational-therapies-for-glaucoma-and-amd/2479457/Visus Therapeutics announced it has entered into a worldwide exclusive licensing agreement with Cella Therapeutics to develop an array of investigational ophthalmic therapies to treat glaucoma and age-related macular degeneration (AMD). The company also announced a worldwide exclusive licensing a
- Eyevensys Raises $12M in a Series B Plus Funding Roundhttps://modernod.com/news/eyevensys-raises-12m-in-a-series-b-plus-funding-round/2479435/Eyevensys announced it has raised $12 million in a Series B Plus funding round. Korea Investment Partners is leading the Series B Plus financing and existing investors will also join the round. The financing will support Eyevensys’ accelerated development of its EYS809 program for the tr
- US Phase 2 Study Published in OSLI Retina Highlights the Safety and Efficacy of Risuteganib in Patients with Dry AMDhttps://modernod.com/news/us-phase-2-study-published-in-osli-retina-highlights-the-safety-and-efficacy-of-risuteganib-in-patients-with-dry-amd/2479429/Allegro Ophthalmics announced that the results of the company’s US phase 2a risuteganib non-exudative age-related macular degeneration (dry AMD) study are published in Ophthalmic Surgery, Lasers, and Imaging (OSLI) Retina. Entitled
- Oyster Point Pharma Names Donald Santel as Chairman of the Board of Directorshttps://modernod.com/news/oyster-point-pharma-names-donald-santel-as-chairman-of-the-board-of-directors/2479427/Oyster Point Pharma announced the appointment of Donald Santel as non-executive Chairperson and a Director of the company and a member of the Compensation Committee. Mr. Santel joined the Board on July 30, 2021, and will take over as Chairperson as Ali Behbahani, MD, steps down as Ch
- FDA Accepts Application for Genentech’s Faricimab for the Treatment of Wet AMD and DMEhttps://modernod.com/news/fda-accepts-application-for-genentechs-faricimab-for-the-treatment-of-wet-amd-and-dme/2479419/Genentech announced that the FDA has accepted the company’s Biologics License Application (BLA), under Priority Review, for faricimab for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). The FDA has also accepted the company’s submission for diabetic r
- New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopiahttps://modernod.com/news/new-data-presented-on-the-safety-and-efficacy-of-investigational-agn-190584-as-a-potential-novel-treatment-for-presbyopia/2479409/Allergan announced new data, including the full results from the phase 3 GEMINI 1 clinical study, evaluating the efficacy, safety and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. Multiple data presentations at the 2021